Ignite Creation Date:
2024-05-06 @ 2:14 AM
Last Modification Date:
2024-10-26 @ 11:15 AM
Study NCT ID:
NCT01999972
Status:
COMPLETED
Last Update Posted:
2020-09-24
First Post:
2013-11-26
Brief Title:
A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A PHASE 1B OPEN LABEL DOSE ESCALATION STUDY TO EVALUATE SAFETY PHARMACOKINETICS AND PHARMACODYNAMICS OF AXITINIB AG-013736 IN COMBINATION WITH CRIZOTINIB PF-02341066 IN PATIENTS WITH ADVANCED SOLID TUMORS
Status:
COMPLETED
Status Verified Date:
2020-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Despite the success of anti-angiogenic therapy in multiple treatment settings a fraction of patients are refractory to vascular endothelial growth factor VEGF inhibitor treatment while the majority of patients will eventually develop evasive resistance It is proposed that mesenchymal-epithelial transition factor c-MET and its ligand hepatocyte growth factor HGF or scatter factor contribute to VEGF inhibitor resistance such that combining a c-MET inhibitor with a VEGF inhibitor will provide additional clinical activity compared to VEGF inhibitor alone This hypothesis will be tested using the cMETALK inhibitor crizotinib in combination with the VEGF inhibitor axitinibSince this will be the first study of axitinib given in combination with crizotinib the study will primarily assess the safety and tolerability of the combination regimen
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2015-001724-31 | EUDRACT_NUMBER | None | None |